Glucotrack Announces USPTO Notice of Allowance for Patent Application Covering Its Implantable CBGM Platform
Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association's 2026 Scientific Sessions
Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology
Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology
Glucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring Technology
Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
Short Interest in GlucoTrack, Inc. (NASDAQ:GCTK) Increases By 53.5%
Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones
Glucotrack to Present at LSI USA '26 Medtech Innovation Summit
Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM Platform
GlucoTrack (NASDAQ:GCTK) Trading 2.9% Higher – Here’s What Happened
Glucotrack, Inc. Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Institutional Investor
GlucoTrack (NASDAQ:GCTK) Stock Price Down 2.2% – Here’s What Happened
GlucoTrack (NASDAQ:GCTK) Stock Price Down 7.5% – Here’s What Happened
Glucotrack Reports Third Quarter 2025 Financial Results and Provides Update on Recent Corporate Highlights
Glucotrack, Inc. Encourages Shareholders to Vote
Glucotrack Appoints Neuromodulation and Painful Diabetic Neuropathy Expert, Usman Latif, MD, MBA, to Clinical Advisory Team
Glucotrack, Inc. Reminds Shareholders to Vote
Glucotrack to Participate in the Q3 Virtual Investor Summit
Glucotrack Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
Glucotrack Expands Clinical Advisory Team Appointing David S. Hirsh, MD as Medical Director, Cardiology
Glucotrack to Exhibit at 2025 Association of Diabetes Care and Education Specialists Annual Meeting
Glucotrack Announces Repurchase of Series A Warrants
Why Is This Nano-Cap Glucotrack Stock Trading Higher On Wednesday?
Glucotrack and OneTwo Analytics Present Positive Final Results of First-In-Human Study for Continuous Blood Glucose Monitor at American Diabetes Association's 85th Scientific Sessions
Glucotrack Announces Reverse Stock Split Shareholder Approved Action Meets NASDAQ Panel Hearing Listing Requirements
Glucotrack to Showcase Long-Term Continuous Blood Glucose Monitor at American Diabetes Association's 85th Scientific Sessions
Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD
Glucotrack Establishes Patient Advisory Board to Inform Diabetes Technology Development
Glucotrack Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
Glucotrack Announces Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose Monitor
Glucotrack to Participate in FORGETDIABETES, a Prominent European Research Initiative to Develop a Bionic Pancreas
Glucotrack and OneTwo Analytics to Collaborate for Clinical Study Analysis on Its Continuous Blood Glucose Monitor
Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights
Glucotrack to Present First-In-Human Study Results for Continuous Blood Glucose Monitor at the 2025 International Conference on Advanced Technologies & Treatment for Diabetes
Glucotrack Appoints Guillermo Umpierrez, MD, CDCES, FACE, MACP as New Medical Advisory Board Member
Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering
Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor
Glucotrack Strengthens Leadership Team with Appointment of New Chief Financial Officer
Glucotrack Announces ISO 13485:2016 Certification
Glucotrack Strenghtens Leadership Team with Addition of Industry Veteran as Vice President of Regulatory Affairs
Glucotrack to Present at TechBio Showcase™ 2025
GLUCOTRACK ANNOUNCES START OF ENROLLMENT FOR HUMAN CLINICAL STUDY OF CONTINUOUS BLOOD GLUCOSE MONITOR
Glucotrack, Inc. Announces Closing of $10.0 Million Public Offering and Concurrent Private Placement Converting $4.0 in Outstanding Debt
GLUCOTRACK TO PRESENT AT 2024 BIOFUTURE CONFERENCE
GLUCOTRACK ANNOUNCES ORAL & POSTER PRESENTATIONS AT THE 2024 DIABETES TECHNOLOGY MEETING
JOHN BALLANTYNE, FORMER BIOTECHNOLOGY EXECUTIVE, JOINS THE GLUCOTRACK BOARD OF DIRECTORS
Glucotrack's Innovative Blood Glucose Monitoring Concept Resonates with Patients with Diabetes, According to New Survey Presented at Association of Diabetes Care and Education Specialists (ADCES) 2024 Annual Conference
GLUCOTRACK ANNOUNCES POSTER PRESENTATION ON CONTINUOUS BLOOD GLUCOSE MONITOR SURVEY DATA AT THE ASSOCIATION OF DIABETES CARE AND EDUCATION SPECIALISTS (ADCES) 2024 ANNUAL CONFERENCE